Medicines Manufacturing Industry Partnership Chair responds to Budget

Andy Evans, Macclesfield Site Manager at AstraZeneca and Chair of the Medicines Manufacturing Industry Partnership has responded to the proposal in the Budget for investment in medicine manufacturing technologies

This investment comes from the part of the first phase of the "Industrial Strategy Challenge Fund", which sets aside £270m for research in the field, alongside robotics and next-generation batteries.

"We welcome the Government's recognition in the Budget of the potential of new medicines manufacturing technologies, as well as the promise of Advanced Therapies. We look forward to working with Government to develop the detail of how these technologies will be supported.

"The next generation of medicines, including medicines tailored to individual patients and cell and gene therapies, are already here. The UK has played a leading role in researching and developing these therapies. This commitment from Government is a welcome first step in ensuring that the UK economy benefits from the manufacture of these medicines, the next important step will be to see patients in the UK benefitting from their potential."



About the ​MMIP

The Medicines Manufacturing Industry Partnership (MMIP) represents the voice of medicines manufacturers in the UK. It was established jointly by Government and the biopharmaceutical industry in 2014 to ensure that the UK is recognised by the global medicines industry as a world-class, advanced centre for medicines manufacturing. MMIP is supported by the Association of the British Pharmaceutical Industry (ABPI), the BioIndustry Association (BIA) and Knowledge Transfer Network (KTN), and includes leadership from Allergan Biologics, AstraZeneca, Eisai, FUJIFILM Diosynth Biotechnologies, GlaxoSmithKline, Pfizer and ReNeuron.​

More within